Compare Cassava Sciences Inc (FLNA) vs GameStop Corp. (GME) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

GME trades at $24.58, down 0.73% on the day, with a bullish technical signal from moving averages and strong insider buying. Revenue declined to $3.82B in 2025, but net income improved to $131.3M with a 25.16% net margin. Recent news highlights CEO Ryan Cohen's aggressive share purchases, fueling positive sentiment.

Outlook hinges on execution of the high-margin collectibles pivot and eBay acquisition potential. Risks include revenue volatility and competitive pressures. Analysts are cautious with 55.55% hold ratings, but insider confidence offers a bullish counter-narrative.